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Copper plays an important role in the aetiology and growth of tumours and levels of the metal are
increased in the serum and tumour tissue of patients affected by a range of cancers including prostate
cancer (PCa). The molecular mechanisms that enable cancer cells to proliferate in the presence of ele-
vated copper levels are, therefore, of key importance in our understanding of tumour growth progression.
In the current study, we have examined the role played by the amyloid precursor protein (APP) in
mitigating copper-induced growth inhibition of the PCa cell line, DU145. A range of APP molecular
constructs were stably over-expressed in DU145 cells and their effects on cell proliferation in the
presence of copper were monitored. Our results show that endogenous APP expression was induced by
sub-toxic copper concentrations in DU145 cells and over-expression of the wild-type protein was able
to mitigate copper-induced growth inhibition via a mechanism involving the cytosolic and E1 copper
binding domains of the full-length protein. APP likely represents one of a range of copper binding
proteins that PCa cells employ in order to ensure efﬁcient proliferation despite elevated concentrations
of the metal within the tumour microenvironment. Targeting the expression of such proteins may
contribute to therapeutic strategies for the treatment of cancers.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The role of copper in the aetiology and growth of tumours has
been extensively studied over the last two decades based initially
on reports that serum and tumour levels of the metal are signiﬁ-
cantly elevated in cancer patients compared to healthy subjects
[1]. At the molecular level, copper may contribute to cancer pro-
gression via a number of mechanisms including oxidative stress-
mediated cell damage or the stimulation of angiogenesis [1]. Thus,
the mechanisms by which cancer cells might regulate their resis-
tance to enhanced copper levels within the tumour microenviron-
ment are of great importance to disease development.The amyloid precursor protein (APP) has achieved notoriety for
its role in the pathogenesis of the neurodegenerative condition,
Alzheimer’s disease (AD). Three major isoforms of the protein are
expressed in human tissues, APP695, APP751 and APP770 [2]. The
main components of the extracellular senile plaques in the AD-
afﬂicted brain are amyloid beta (Ab)-peptides which are derived
from APP through two sequential proteolytic cleavages by b-secre-
tase (b-site APP-cleaving enzyme 1; BACE1) and the c-secretase
complex [2]. The initial soluble product generated by b-secretase
is termed sAPPb (soluble APP beta). In contrast to this ‘amyloido-
genic’ pathway, APP is also processed via a non-amyloidogenic
route involving a-secretase cleavage within the Ab domain [2].
This latter cleavage precludes Ab-peptide formation and generates
a sAPPa (soluble APP alpha) fragment.
More recently, APP has been shown to play a role in cancer.
Expression of the protein stimulates colon carcinoma cell prolifer-
ation [3] and an increase in APP mRNA expression in oral squa-
mous cell carcinomas is associated with a reduction in patient
survival [4]. Thyroid cancers are characterised by up regulation
of APP protein and mRNA expression [5] with the former also being
enhanced in pancreatic cancer tissue specimens [6].
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been shown to enhance the proliferation of the prostate cancer
(PCa) cell line, LNCaP [7]. More recently, Miyazaki et al. [8] pub-
lished data in this journal demonstrating that the proliferation
and invasion of two PCa cell lines (LNCaP and DU145) were
impaired following depletion of the endogenous protein.
APP is a copper binding protein that has been implicated in cel-
lular copper homeostasis [9] and several reports exist speciﬁcally
demonstrating increased copper levels in the whole blood, plasma
or serum of prostate cancer (PCa) patients [10–12]. Therefore, in
the current study, we have investigated the ability of APP to miti-
gate the copper-induced growth inhibition of the brain metastatic
PCa cell line, DU145. Although metastasis of PCa cells to the brain
is a relatively uncommon event, it is increasing in prevalence prob-
ably as a consequence of increased patient survival times due to
new drug regimes. Furthermore, the brain exhibits high copper
concentrations second only to the liver [13] making DU145 cells
a particularly appropriate cell line for the current type of study.
Our results show that the endogenous expression of APP was
enhanced by copper in DU145 cells and that the over-expression
of any of the three major APP isoforms mitigated copper-induced
growth inhibition. Furthermore, we have shown that membrane
anchorage of APP and intact cytosolic and E1 copper binding
domains are all molecular pre-requisites in this respect. Thus,
APP might represent one of a range of copper binding proteins uti-
lised by cancer cells to promote growth in the presence of elevated
copper concentrations within the tumour microenvironment.2. Materials and methods
2.1. Materials
Anti-APP C-terminal and anti-actin monoclonal antibodies were
from Sigma–Aldrich (Poole, U.K.). Anti-APP 6E10 monoclonal anti-
body was from Cambridge Bioscience Ltd. (Cambridge, U.K.) and
anti-sAPPb (1A9) antibody was kindly provided by Ishrut Hussain
(GlaxoSmithKline, Harlow, U.K.). APP mutant DNA constructs were
either synthesized in-house by site-directed mutagenesis of a
wild-type APP695 template or de novo by Epoch Life Science Inc.
(Missouri City, U.S.A.). All other materials, unless otherwise stated,
were from Sigma–Aldrich (Poole, U.K.).2.2. Cell culture
All cell culture reagents were purchased from Lonza Ltd. (Basel,
Switzerland). DU145 cells were cultured in Roswell Park Memorial
Institute 1640 medium supplemented with 25 mM glucose, 4 mM
L-glutamine, 10% (v/v) foetal bovine serum, penicillin (50 U/ml),
streptomycin (50 mg ml1), and fungizone (2.5 mg ml1). Cells
were maintained at 37 C in 5% CO2 in air. Stable DU145 transfec-
tants were generated using the Amaxa cell line Nucleofector Kit L
in a Nucleofector 2b device (Lonza Ltd., Basel, Switzerland) and
subsequent selection of stable transfectants was performed using
hygromycin B (200 lg ml1). For the experiments involving the
truncated sAPPa and sAPPb constructs, plasmids were stably
expressed in SH-SY5Y (sAPPa) or HEK (sAPPb) cells. Medium
conditioned for 48 h on mock-, sAPPa- and sAPPb-transfected cells
was then harvested, centrifuged at 100,000g for 1 h, and concen-
trated 50-fold in centrifugal concentrators (Sartorius, Epsom,
U.K.) before being reconstituted to the original volume in
Opti-MEM (Lonza Ltd., Basel, Switzerland). This reconstituted,
pre-conditioned medium was then used to culture DU145 cells in
the absence or presence of copper for 7 days with the medium
being replaced with fresh pre-conditioned medium every two
days. Copper (either free CuCl2 or glycine:copper complexes) waspre-incubated at the indicated ﬁnal concentrations for 1 h with
complete growth medium prior to the addition of the medium to
cells.
2.3. Cell viability assay
Cell proliferation was examined using methanethiosulfonate
(MTS) (Promega, Wisconsin, U.S.A.) or by counting cells using Try-
pan blue staining. At the time points indicated, cells were incu-
bated with CellTiter 96 AQueous One Cell Proliferation Assay
(MTS) solution for 2 h at 37 C. Absorbance readings at 492 nm
were then taken using an Anthos 2020 microplate reader (Perkin-
Elmer, Massachusetts, U.S.A.).
2.4. Protein assay, sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS–PAGE) and immunoblot analysis
Protein was quantiﬁed using bicinchoninic acid [14] in a micro-
titre plate with bovine serum albumin as a standard. Proteins were
resolved by SDS–PAGE and transferred to Immobilon P polyvinyli-
dene diﬂuoride membranes as previously described [15]. Anti-APP
C-terminal antibody was used at a dilution of 1:7500, anti-actin at
1:5000, anti-APP 6E10 at 1:2500 and anti-sAPPb (1A9) at 1:3000.
Bound antibody was detected using peroxidase-conjugated sec-
ondary antibodies (Sigma–Aldrich, Poole, U.K. and R&D Systems
Europe Ltd., Abingdon, U.K.) in conjunction with enhanced chemi-
luminescence detection reagents (Perbio Science Ltd, Cramlington,
U.K.).
2.5. Statistical analysis
All data are presented as the means ± S.D. or S.E.M. Data were
subjected to statistical analysis via Student’s t-test. Levels of signif-
icance are indicated in the ﬁgure legends.
3. Results and discussion
3.1. Copper inhibits DU145 cell proliferation and enhances endogenous
APP expression
Initially we examined the inhibitory effect of copper on the
growth of untransfected DU145 cells by culturing them in com-
plete growth medium containing various metal concentrations
(results were identical whether metal was added to growth med-
ium in the form of free CuCl2 or glycine-complexed copper).
DU145 cells were fundamentally very resistant to copper with no
signiﬁcant inhibition of growth being apparent at metal concentra-
tions of 100 lM and lower (Fig. 1A). At 150 lM copper, growth
inhibition became apparent at 4 days and persisted for the entire
7 day growth period whilst very little growth occurred at all in
the presence of 200 lM copper. The authors concede that levels
of copper within the tumour microenvironment are unlikely to
exceed 30 lM [1] at which concentration tumour cells are clearly
able to maintain copper homeostasis through a range of possible
mechanisms [16]. However, it is only when these mechanisms
are overloaded at higher metal concentrations (as in the current
study) that individual elements of these mechanisms can be tested.
We next examined whether the expression of endogenous APP
could be enhanced by copper as observed previously in non-
cancerous cell lines [17]. Immunoblot analysis of lysates prepared
from DU145 cells cultured in the presence of various copper
concentrations demonstrated that APP expression was enhanced
at metal concentrations as low as 10 lM (Fig. 1B) and peaked at
50 lM; at which point levels of the protein were increased
2.74 ± 0.48-fold relative to those in lysates from untreated cells
(Fig. 1C). Thus, it is possible that DU145 cells increase their
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Fig. 1. Copper-induced growth inhibition and wild-type APP expression in DU145 cells. (A) Untransfected DU145 cells were cultured over a 7 day period in the absence/
presence of the indicated copper concentrations. At various time points, cell viability was assayed as described in the Section 2. Results are expressed relative to viability at
day 0. (B) Immunoblot of APP and actin expression in lysates prepared from untransfected DU145 cells cultured for 7 days in medium containing the indicated copper
concentrations. (C) Quantiﬁcation of endogenous APP expression in DU145 cells cultured for 7 days in the absence or presence of copper (50 lM). Results are expressed
relative to APP expression levels in the untreated control (no metal). (D) DU145 cells stably transfected with either vector alone (Mock) or wt-APP695 (WT-APP) were cultured
over a 7 day period in the absence or presence of copper (150 lM). At the various time points, cell viability was assayed as described in the Section 2. Results are expressed
relative to viability at day 0. (E) DU145 cells stably transfected with either vector alone (Mock) or the indicated APP isoform were cultured over a 7 day period in the presence
of copper (150 lM). At 7 days lysates were prepared and immunoblotted for APP and actin and cell viability was determined as described in the Section 2. Results are
expressed relative to the viability of Mock-transfected cells cultured in the presence of copper at day 7. All results are means ± S.D. (n = 3). *, ** and *** Denote signiﬁcance at
P = 0.05, P = 0.01 and P = 0.005, respectively.
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cytotoxicity.
3.2. Wild-type APP mitigates copper-induced growth inhibition in
DU145 cells regardless of isoform type
Having determined the threshold concentration at which cop-
per inhibited DU145 cell growth, we next sought to examine
whether the over-expression of wild-type (wt)-APP could mitigate
this effect. DU145 cells stably transfected with either vector alone
(Mock) or wt-APP695 were cultured in the absence or presence of150 lM copper. The results (Fig. 1D) show that APP695 did not pro-
mote growth in the absence of exogenous copper. However, whilst
the growth of mock-transfected cells was inhibited by copper, the
over-expression of APP695 completely mitigated this effect. As
DU145 cells mainly express the larger APP751 and APP770 isoforms
(with lower levels of APP695), we also examined the isoform
speciﬁcity of this phenomenon. Following the generation of
stable transfectants, all three APP isoforms were found to be
over-expressed at similar levels (Fig. 1E). Furthermore, all three
isoforms increased cell growth in the presence of copper
(150 lM) (Fig. 1E).
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employed. All constructs were based on the 695 amino acid isoform of wild-type (wt)-APP. The sAPPa construct is analogous to soluble APP cleaved from the holoprotein by
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744 M. Gough et al. / Biochemical and Biophysical Research Communications 453 (2014) 741–747It is interesting to note that, in the current over-expression
study, we did not ﬁnd that APP increased DU145 cell proliferation
in the absence of exogenous copper. Prima facie, this ﬁnding might
seem at odds with recent data reported by Miyazaki et al. [8] which
showed that the depletion of endogenous APP using siRNA in
DU145 cells reduced cell proliferation. One possible explanation
for this apparent discrepancy might be that only a threshold level
of endogenous APP expression is required to promote cell growth
in the absence of copper such that enhancing expression further
by APP transfection has no additive effect on growth. Only when
the cells are exposed to copper insult might additional APP be
required to mitigate the resultant metal-induced growth
inhibition.3.3. Soluble forms of APP are not sufﬁcient to mitigate copper-induced
growth inhibition
Next we sought to determine which parts of the APP molecule
were prerequisites for the mitigation of copper-induced growth
inhibition. Initially we examined whether soluble forms of the pro-
tein could exert a similar effect to that of full-length APP using con-
structs analogous to sAPPa (truncated C-terminally to lysine612)
and sAPPb (truncated C-terminally to methionine 596) (Fig. 2A).
Note that all molecular constructs were based on the 695 amino
acid APP isoform. Unfortunately, when these soluble constructs
were expressed in DU145 cells, the products were aberrantly
processed intracellularly (data not shown). However, when
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structs were secreted as the predicted fragments of approximately
110 kDa (Fig. 2B and C). We, therefore, cultured mock-transfectedDU145 cells in pre-conditioned medium from the HEK or SH-
SY5Y stable transfectants (see Section 2) in the absence or presence
of copper. The results (Fig. 2D) show that the growth of cells was
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medium. Also of note is the fact that a- and b-secretase inhibitors
had no effect on the growth of wt-APP-transfected DU145 cells in
the presence of copper (data not shown). Collectively, these data
indicate that the full-length form of APP is a prerequisite for the
mitigation of copper-induced growth inhibition in DU145 cells.
3.4. Tyrosines 682 and 687 within the APP intracellular domain are
pre-requisites for the mitigation of copper-induced growth inhibition
The fact that soluble forms of APP failed to mitigate copper-
induced growth inhibition suggested that the intracellular domain
(ICD) of the protein might be a prerequisite in this respect. There-
fore, we generated a construct (APPDICD) truncated C-terminally
to residue 648 (Fig. 3A). In order to narrow down any potential
involvement of the APP ICD even further, we also examined the
role of two cytosolic tyrosine residues within this domain
(tyrosines682 and 687) the phosphorylation of which might be
linked to cell signalling. To this end, three further constructs were
generated; APP Y682G, APP Y687G and APP Y682 + 687G (Fig. 3A).
Following transfection of the constructs into DU145 cells, the hol-
oprotein expression levels and generation of sAPPa were indistin-
guishable from those of wt-APP695 (Fig. 3B and C). However, no
sAPPb was generated from APPDICD (Fig. 3B) which was probably
indicative of the fact that the APP ICD is required for internalisationof the protein and subsequent b-secretase cleavage. Reduced levels
of sAPPb generation were also observed in the case of the tyrosine
mutant constructs (Fig. 3C) indicating that these residues are spe-
ciﬁcally linked to the generation of this fragment. However, given
our previous results showing that sAPPb had no effect on DU145
cell growth in the presence of copper (Fig. 2) the reduced genera-
tion of this fragment from the cytosolic domain constructs is unli-
kely to have impacted on cell growth. The reduced growth of cells
expressing these constructs in the presence of copper (relative to
wt-APP-transfected cells) (Fig. 3D) was, therefore, most likely
due to changes in the nature of the APP intracellular domain.
3.5. The APP E1 copper binding domain is a pre-requisite for the
mitigation of copper-induced growth inhibition
Finally, we examined the role of the copper binding domain
(CuBD) in the E1 extracellular domain of APP. We generated a con-
struct (APPDCuE1) in which three histidines were mutated to ala-
nine in a key area of the protein associated with copper binding
[18] (Fig. 4A). This construct was expressed and processed in
DU145 cells in a manner identical to that of wild-type APP695
(Fig. 4B). However, APPDCuE1 failed to mitigate copper-induced
growth inhibition (Fig. 4C) indicating that the extracellular E1
CuBD, in addition to the cytosolic domain, of APP were prerequi-
sites in this respect.
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Our results indicate that APP is one element in a potential range
of biochemical mechanisms by which cancer cells are able to pro-
liferate efﬁciently despite the presence of elevated copper levels
within the tumour microenvironment. DU145 cells, in particular,
are able to increase their expression of the protein as a response
to physiologically relevant concentrations of copper. At the molec-
ular level, the ability of APP to mitigate copper-induced growth
inhibition requires an intact E1 CuBD within the extracellular
domain and probably involves a signalling pathway mediated by
the phosphorylation of tyrosine residues within the cytosolic
domain of the protein.Acknowledgments
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